CALLDORADO
Calldorado has acquired longstanding partner Appvestor in a deal that will give its community of app developers instant access to advanced user acquisition tools.
The two companies make a good fit. Both are dedicated to helping app makers grow but in different ways. Calldorado’s unique technology helps Android developers keep existing user bases active and monetize them. Meanwhile, Appvestor’s AI-powered tools help them find new customers.
Appvestor was established in 2017 to build a technology engine that deploys machine learning and predictive algorithms to establish the best destinations for paid marketing campaigns. Its complete service to developers includes:
- A technology engine that maps campaign progress against revenue, conversion, and retention at a user level.
- Experience in running marketing campaigns that deliver large volumes of new users and the highest return on investment.
- Access to creative resources including studio and production.
- Expertise in ASO (App Store Optimization), which boosts the impact of campaigns and the number of customer conversions.
Calldorado has been working closely with Appvestor since its launch. Mathias Schroeder, co-CEO and co-founder of Calldorado, believes the buy-out is a logical move for both parties. He says: “Our tech does a brilliant job of keeping app users engaged. But it doesn’t find new ones. That’s why we have worked with many user acquisition platforms in the past.
"Appvestor was always the best. It’s the only one with predictive algorithms that can dynamically adjust a marketing campaign to maximize return on investment at all times. Paid user acquisition is a key strategic asset for us, so acquiring Appvestor makes perfect sense. We can’t wait to combine the two companies’ skills into a service that can really help scale our first-party and customer apps.”
The acquisition comes at a time of rapid growth in the app market. Total app downloads across both iOS and Google Play hit 130 billion (1 ). This was a 10% increase on 2019.
Meanwhile, total consumer spend on apps (in-app purchases, subscriptions, and premium apps) reached $143 billion in 2020 – up 20% in a year. App Annie believes the total could hit $270 billion by 2025.
The buoyant app market has fuelled a fast-growing app install ad sector. Developers increasingly rely on paid marketing to drive installs. So much so that analysts expect the total spend to rise from $57.8 billion in 2019 to $118 billion in 2022 (2).
About Calldorado
Calldorado’s unique user activation and monetization technology, the Caller SDK, helps Android app publishers keep their app user bases active, drives incremental traffic, and maximizes app revenue. Calldorado also publishes first-party apps; it launched its own content business with the acquisition of CIAmedia in 2018. A year later it acquired the call enrichment specialist adaffix. Calldorado was established in 2016 with headquarters in Denmark and is privately held.
1. Source: App Annie – State of Mobile 2021 https://www.appannie.com/en/go/state-of-mobile-2021/
2. Source: Appsflyer https://www.appsflyer.com/blog/trends-insights/app-install-ad-spend/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005536/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
